Recursion Pharmaceuticals: A Most Curious Speculation

Recursion, a healthcare enterprise dabbling in the algorithmic arts, promises a revolution in drug discovery. It’s a charming notion, though one must always suspect that promises, like perfumes, lose their potency upon closer inspection. The company’s operating system, a digital oracle of sorts, attempts to divine which clinical compounds might survive the gauntlet of trials and regulations. A noble pursuit, to be sure, but one that has, thus far, yielded little more than elegantly charted failures.








